Zymeworks Inc (ZYME)
12.57
+0.38
(+3.12%)
USD |
NASDAQ |
Oct 04, 16:00
12.56
-0.01
(-0.08%)
After-Hours: 20:00
Zymeworks Research and Development Expense (Annual): 143.62M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 143.62M |
| December 31, 2022 | 208.60M |
| December 31, 2021 | 199.75M |
| December 31, 2020 | 171.20M |
| December 31, 2019 | 117.37M |
| Date | Value |
|---|---|
| December 31, 2018 | 56.93M |
| December 31, 2017 | 41.14M |
| December 31, 2016 | 36.82M |
| December 31, 2015 | 24.65M |
| December 31, 2014 | 12.62M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
117.37M
Minimum
2019
208.60M
Maximum
2022
168.11M
Average
171.20M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Johnson & Johnson | 15.08B |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.40M |
| iBio Inc | 5.185M |
| Theriva Biologics Inc | 14.31M |